Be the first person to write a business review for Response Genetics Inc.

Roche Diagnostics Corporation company was founded in 1998 and is headquartered in Indianapolis, Indiana. Roche Diagnostics Corporation operates as a subsidiary of Roche Holding AG. Roche Diagnostics Corporation offers diagnostic tests and systems. The company operates in the diagnostic areas of diabetes care, centralized diagnostics, applied science, molecular diagnostics, and point-of-care diagnostics. Its products include diagnostics tools that test for congestive heart failure, HIV, Hepatitis B and C, fertility, and diabetes diseases. The company supplies its products to researchers, physicians, patients, hospitals, and laboratories. It has facilities in Indiana, New Jersey, South Carolina, Colorado, New Hampshire, Puerto Rico, and California, as well as locations in Canada.

Roche s.r.o in the Czech Republic is just a hop, skip, and a jump away from parent company Roche Holding Ltd. in nearby Switzerland. Its operations are focused more on the parent company's diagnostic products than on its traditional pharmaceuticals; Roche s.r.o. has two facilities in Prague for manufacturing and distributing tests for Hepatitis B and C, HIV, cancer, and other diseases. One is devoted exclusively to diabetic products -- diabetes is a growing problem in the Czech Republic. Roche s.r.o. also markets pharmaceuticals made at other Roche facilities, including such popular therapies as cancer drugs Avastin and Herceptin, lymphona drug MabThera, and osteporosis drug Bonviva.

Rosetta Genomics Ltd. was founded in 2000 and is based in Rehovot, Israel.Rosetta Genomics Ltd. develops microRNA-based diagnostic and therapeutic products in Israel. MicroRNAs are naturally expressed, or produced, using instructions encoded in DNA and are used in regulating protein production. The company develops microRNA-based diagnostic programs for various cancers, as well as for the identification of the origin of the primary tumor of metastases; for differentiating squamous from non squamous non-small cell lung cancer; and for differentiating mesothelioma from other carcinomas in the lung and pleura. The company also focuses on the development of minimally/non-invasive, blood or serum-based molecular diagnostics tests. In addition, it develops microRNA-based therapeutic products for the treatment of liver cancer and chronic infections. The company has a license and collaboration agreement with Prometheus Laboratories Inc. to license and sublicense certain rights related to the company's microRNA-based cancer diagnostic tests; and a testing and administrative services agreement with Teva Pharmaceutical Industries Ltd. to distribute these tests in Turkey and Israel.

Rubicon Genomics, Inc. was founded in 2000 and is based in Ann Arbor, Michigan. Rubicon Genomics, Inc. engages in the development and commercialization of pre-analytical and analytical kits and licenses to improve genetic, epigenetic, and expression analysis in research, diagnostic, and other clinical applications. It offers GenomePlex whole genome amplification platform, a research and diagnostic pre-analytical tool to amplify and standardize DNA for genetic analysis; TransPlex whole transcriptome amplification platform, which amplifies and standardizes RNA sequences for expression analysis; and MethylPlex platform, which amplifies and standardizes the methylated portion of DNA for methylation analysis. The company also provides kits for research and diagnostics applications; contract services to biotech, pharma, and diagnostic companies and institutions; OEM reagents for diagnostic manufacturing; partnerships to develop and commercialize cancer biomarkers and tests; out-licenses for cancer biomarkers; and out-licenses for kits and processes. In addition, it offers fee-for-service products, including whole genome amplification services, single-cell whole genome amplification services, whole transcriptome amplification services, and methylated DNA amplification and analysis services. The company serves pharmaceutical, biotechnology, diagnostic, government, academic, and research institutions.

Rules-Based Medicine, Inc. company was founded in 1998 and is headquartered in Austin, Texas. Rules-Based Medicine, Inc., a life sciences company, focuses on the development and commercialization of molecular diagnostic tests based on novel biomarker patterns primarily for the psychiatric market. It develops molecular diagnostic tests using its proprietary multi-analyte profiling, or MAP, technology that helps to screen large sets of well-characterized clinical samples from both diseased and non-diseased populations against a menu of biomarker immunoassays. The company’s pharmaceutical services consist of MAP testing services, custom MAP services, multiplexed immunoassay kits, and TruCulture and other co-culture services. It markets its laboratory testing products and services primarily to drug development professionals at pharmaceutical and biotechnology companies.

Inviting Real Estate Agents, Job Placements Agents, Educational Institutes, Software Service Providers, Real Estate Builders, Marriage Bureaus, Travel Agents, Restaurant Owners, Health & Fitness Centers and other Local Businesses to Post a FREE Classified Advertisement on Cootera.com Classifieds Website.